Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Sphingosine-1-Phosphate Receptors

Known as: Sphingosine-1-Phosphate Receptor, Receptor, Sphingosine 1 Phosphate, Sphingosine 1 Phosphate Receptor 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Sphingosine 1-phosphate receptor (S1PR) modulators possess a unique mechanism of action in the treatment of multiple sclerosis… Expand
  • figure 1
  • figure 2
  • table 1
  • table 3
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Significance Secondary progressive multiple sclerosis (SPMS) inflicts severe and irreversible disability on the affected… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2017
Highly Cited
2017
Bile duct obstruction is a potent stimulus for cholangiocyte proliferation, especially for large cholangiocytes. Our previous… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Sphingosine 1-phosphate binds and stabilizes telomerase, a process that could be targeted to promote senescence and reduce cancer… Expand
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Purpose: Although the anti–EGF receptor (EGFR) monoclonal antibody cetuximab is an effective strategy in colorectal cancer… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2011
Highly Cited
2011
The sphingolipid metabolites ceramide and sphingosine-1-phosphate (S1P) have recently been implicated in autophagy. In this study… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Review
2011
Review
2011
Until recently, all approved multiple sclerosis (MS) disease treatments were administered parenterally. Oral fingolimod was… Expand
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Agonists of the sphingosine-1-phosphate receptor (S1PR) attenuate kidney ischemia-reperfusion injury (IRI). Previous studies… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2006
Highly Cited
2006
FTY720 is an immunomodulator with demonstrated efficacy in a phase II trial of relapsing multiple sclerosis. FTY720-phosphate… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2001
Highly Cited
2001
The lysophospholipids sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) stimulate cellular proliferation and affect… Expand
Is this relevant?